The DJS Law Group announces that it is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (“Larimar” or “the Company”) (NASDAQ: LRMR) for violations of the securities laws.

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. On September 29, 2025, Larimar released data from an open-label study of daily subcutaneous injections of Nomlabofusp in patients with Friedreich's Ataxia. Although the Company portrayed the results as positive, multiple study participants suffered severe allergic reactions to the treatment. Based on this news, shares of Larimar fell by 33.66%.

If you are a shareholder who suffered a loss, contact us to participate.

WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251015763463/en/